Tags

Type your tag names separated by a space and hit enter

Pituitary apoplexy: a rare complication of leuprolide therapy in prostate cancer treatment.
BMJ Case Rep. 2017 Jul 14; 2017BC

Abstract

Gonadotropin-releasing hormone agonists, used widely in the treatment of metastatic prostate cancer and hormone receptor-positive breast cancer, are associated with a rare but potentially fatal outcome of pituitary apoplexy (PA). An 85-year-old man presented with sudden onset of headache, left eye pain, sensitivity to light, nausea and vomiting. The symptoms started 4 hours after initiation of leuprolide therapy for treatment of recently diagnosed metastatic prostate carcinoma. Radiological imaging of the brain demonstrated a heterogeneously enlarged pituitary gland measuring 19×16×13 mm and T1-hyperintense signal compatible with pituitary haemorrhage. Hormone function tests were indicative of panhypopituitarism, confirming the diagnosis of PA. Due to age, the patient was started on hormonal replacement therapy and eventually symptoms improved.

Links

PMC Free PDF

Authors+Show Affiliations

Tanios G
Internal Medicine, East Tennessee State University, Johnson city, Tennessee, USA.
Mungo NA
Internal Medicine, East Tennessee State University, Johnson city, Tennessee, USA.
Kapila A
Internal Medicine, East Tennessee State University, Johnson city, Tennessee, USA.
Bajaj K
Internal Medicine, East Tennessee State University, Johnson city, Tennessee, USA.

MeSH

Aged, 80 and overAntineoplastic Agents, HormonalDiagnosis, DifferentialHeadacheHumansLeuprolideMagnetic Resonance ImagingMalePituitary ApoplexyProstatic Neoplasms

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

28710301

Citation

Tanios, Georges, et al. "Pituitary Apoplexy: a Rare Complication of Leuprolide Therapy in Prostate Cancer Treatment." BMJ Case Reports, vol. 2017, 2017.
Tanios G, Mungo NA, Kapila A, et al. Pituitary apoplexy: a rare complication of leuprolide therapy in prostate cancer treatment. BMJ Case Rep. 2017;2017.
Tanios, G., Mungo, N. A., Kapila, A., & Bajaj, K. (2017). Pituitary apoplexy: a rare complication of leuprolide therapy in prostate cancer treatment. BMJ Case Reports, 2017. https://doi.org/10.1136/bcr-2016-218514
Tanios G, et al. Pituitary Apoplexy: a Rare Complication of Leuprolide Therapy in Prostate Cancer Treatment. BMJ Case Rep. 2017 Jul 14;2017 PubMed PMID: 28710301.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pituitary apoplexy: a rare complication of leuprolide therapy in prostate cancer treatment. AU - Tanios,Georges, AU - Mungo,Nicolas Andrews, AU - Kapila,Aaysha, AU - Bajaj,Kailash, Y1 - 2017/07/14/ PY - 2017/7/16/entrez PY - 2017/7/16/pubmed PY - 2018/4/14/medline KW - Contraindications and precautions KW - Drugs: endocrine system KW - Endocrine system KW - Pituitary disorders KW - Prostate Cancer JF - BMJ case reports JO - BMJ Case Rep VL - 2017 N2 - Gonadotropin-releasing hormone agonists, used widely in the treatment of metastatic prostate cancer and hormone receptor-positive breast cancer, are associated with a rare but potentially fatal outcome of pituitary apoplexy (PA). An 85-year-old man presented with sudden onset of headache, left eye pain, sensitivity to light, nausea and vomiting. The symptoms started 4 hours after initiation of leuprolide therapy for treatment of recently diagnosed metastatic prostate carcinoma. Radiological imaging of the brain demonstrated a heterogeneously enlarged pituitary gland measuring 19×16×13 mm and T1-hyperintense signal compatible with pituitary haemorrhage. Hormone function tests were indicative of panhypopituitarism, confirming the diagnosis of PA. Due to age, the patient was started on hormonal replacement therapy and eventually symptoms improved. SN - 1757-790X UR - https://www.unboundmedicine.com/medline/citation/28710301/Pituitary_apoplexy:_a_rare_complication_of_leuprolide_therapy_in_prostate_cancer_treatment_ DB - PRIME DP - Unbound Medicine ER -